Conferences Feature Desmoid Tumors
DTRF's Patient Registry Poster Wins 1st Place Award at CTOS 2023
The DTRF Patient Registry poster titled, "Characterizing the Patient Journey To Diagnosis of Desmoid Tumor: Desmoid Tumor Research Foundation Natural History Study" was presented at CTOS 2023 by SpringWorks Therapeutics Medical Science Liaison, Mitchell Allen, PhD (pictured with Lynne Hernandez, DTRF Executive Director). It won first place in Category 1: Improving Sarcoma Care Globally. This poster was created in partnership with SpringWorks Therapeutics, under the leadership of the DTRF's Principal Investigator for the Registry, Kelly Mercier, PhD, and the poster's first author Shengfan Zhou, MS (SpringWorks). Congratulations to the entire team from SpringWorks and the DTRF on this important accomplishment!
ASCO 2023
Desmoid tumors were the subject of several poster presentations and discussions during the Sarcoma Track of ASCO 2023, on Saturday, June 3rd. Below is a list of posters with links to their abstracts. The DTRF is grateful for all of the desmoid research that is taking place around the world.
Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.
Thierry Alcindor, MD, MSc, McGill University Health Center, et. al. Abstract: https://meetings.asco.org/abstracts-presentations/218369
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study. Winette T.A. Van Der Graaf, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, et. al. Abstract: https://meetings.asco.org/abstracts-presentations/220655 RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results. Mrinal M. Gounder, MD, Memorial Sloan Kettering Cancer Center, et. al. Abstract: https://meetings.asco.org/abstracts-presentations/218382
11
Made with FlippingBook Online newsletter maker